You have searched for "trial"
Showing 1-10 of 10000
(Reuters) - Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said.
NEW YORK (Reuters) - Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.
KAJANG (Bernama): A salesman pleaded not guilty in the Magistrate's Court here Monday (Nov 30) to a charge of drink driving and causing the death of a factory operator on the Kajang-Seremban Highway (LEKAS) on Friday (Nov 27).
SEOUL (Reuters) - A South Korean court on Monday found former president Chun Doo-hwan guilty of defaming a former democracy activist who was involved in protests against his government in the 1980s and handed him an eight-month suspended jail sentence.
MEXICO CITY (Reuters) - Mexico's attorney general is seeking the extradition from the United States of a former security minister wanted on corruption charges, but only after his U.S. trial is concluded, a local newspaper reported on Sunday.
NEW DELHI/MUMBAI (Reuters) - The Indian Council of Medical Research (ICMR) is assisting an inquiry into an alleged adverse reaction during AstraZeneca's COVID-19 vaccine trial, but has found no reason to recommend halting it, a senior official at the regulator said on Sunday.
NEW DELHI, Nov. 29 (Xinhua) -- The Serum Institute of India (SII) on Sunday rejected the allegation levelled by a COVID-19 vaccine volunteer who sued the company for 5 crore Indian Rupees (around 675,675 U.S. dollars) for having developed side effects.
NEW DELHI, Nov. 29 (Xinhua) -- The financial grant of around 121 million U.S. dollars under the mission dedicated towards development of COVID-19 vaccines would be utilized in research and development of Indian COVID-19 vaccines, an official statement said Sunday.
GENEVA (Reuters) - The World Health Organization needs to see clinical data and information of good manufacturing practice to be able to evaluate Russia's Sputnik V coronavirus vaccine, WHO assistant director general Mariangela Simao said on Friday.